An APRIL to remember: novel TNF ligands as therapeutic targets
Authors:
- Stacey R. DillonSDStacey R. Dillon
- Jane A. GrossJGJane A. Gross
- Stephen M. AnsellSAStephen M. Ansell
- Anne J. NovakANAnne J. Novak
- 10 February 2006
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 5 (3) , 235-246
Abstract
Since their discovery in 1998, the two TNF family members APRIL and BLyS/BAFF have received increasing attention. In addition to regulating normal B-cell development and immune responses, these molecules might be crucial in a diverse set of diseases, including autoimmunity and cancer. Although more has been published about the general biology of BLyS/BAFF than that of APRIL, many recent articles have described novel APRIL biology. Here we focus on APRIL, exploring its normal and pathological functions, and comparing the therapeutic molecules currently under development that target BLyS/BAFF alone, or APRIL and BLyS/BAFF together.Keywords
This publication has 101 references indexed in Scilit:
- Raised serum APRIL levels in patients with systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2005
- Identification of proteoglycans as the APRIL-specific binding partnersJournal of Experimental Medicine, 2005
- Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferationCell Death & Differentiation, 2005
- The Crystal Structure of A Proliferation-inducing Ligand, APRILJournal of Molecular Biology, 2004
- Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2004
- The CD40–CD154 interaction in B cell–T cell liaisonsCytokine & Growth Factor Reviews, 2003
- Crystal structure of the BAFF–BAFF-R complex and its implications for receptor activationNature Structural & Molecular Biology, 2003
- A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosusRheumatology, 2003
- RETRACTED ARTICLE: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRILNature Immunology, 2002
- Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseasesArthritis & Rheumatism, 2001